Bing

Spectrum Pharmaceuticals (NASDAQ:SPPI) was upgraded by Zacks from a “hold” rating to a “buy” rating in a report issued on Wednesday, Market Beat reports. The brokerage presently has a $8.25 target price …
wkrb13.com · 8/28/2015
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) opened at 6.92 on Wednesday. Spectrum Pharmaceuticals, Inc. has a 1-year low of $5.45 and a 1-year high of $8.50. The stock has a 50 day moving average of $7.10 …
Ticker Report · 8/26/2015
Shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) have been assigned an average rating of “Buy” from the six brokerages that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold ...
sleekmoney.com · 8/22/2015
More from Bing News
NEW YORK (TheStreet) -- Shares of Spectrum Pharmaceuticals (SPPI - Get Report) plunged more than 20% to a 52-week low of $5.65 on Monday after a U.S. District Court ruled Friday that patent claims of its Fusilev cancer drug are invalid. The U.S.
The Street · 2/23/2015
Over the last 30 days, the company witnessed two negative estimate revisions and the Zacks Consensus Estimate also moved lower, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday’s move …
ZACKS · 5/13/2015
Zacks upgraded shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) from a hold rating to a buy rating in a research report sent to investors on Friday morning, AnalystRatingsNetwork.com reports. They currently have $8.50 target price on the …
Mideast Times · 8/12/2015
Spectrum Pharmaceuticals, Inc. (SPPI) was a big mover last session, as its shares rose over 10% on the day. The upside came on the back of an encouraging announcement by an activist that the company could fetch more than $7.95 a share in a sale.
Yahoo Finance · 5/13/2015
Small cap cancer stock Spectrum Pharmaceuticals, Inc (NASDAQ: SPPI), who’s performance benchmarks in the cancer space include mid cap Juno Therapeutics Inc (NASDAQ: JUNO) and small cap Merrimack Pharmaceuticals Inc (NASDAQ: MACK) …
Smallcap Network · 7/14/2015
2015 is unlikely to bring the hopes and dreams of a stock recovery that Spectrum Pharmaceuticals (NASDAQ:SPPI) investors so anxiously desire. In late December, Spectrum filed a new drug application for a product that has created quite a bit of buzz …
Seeking Alpha · 3/10/2015
SPPI)’s most prominent drug, Fusilev, to generic competition, the company handed out $2 million in bonuses and salary increments to its top four executives. This came from a company whose stock has slumped by 50% over the last three years, while ...
INSIDER MONKEY · 6/4/2015